Molecular Mechanisms of Tumor Angiogenesis and Tumor Progression
暂无分享,去创建一个
[1] A. Harris,et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[2] J. Folkman,et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[3] G. Christofori,et al. Novel forms of acidic fibroblast growth factor-1 are constitutively exported by β tumor cell lines independent from conventional secretion and apoptosis , 2004, Angiogenesis.
[4] G. Yancopoulos,et al. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. , 1999, Genes & development.
[5] T. L. Moser,et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[6] R. D'Amato,et al. Inhibition of angiogenesis in vivo by interleukin 12. , 1995, Journal of the National Cancer Institute.
[7] Robert S. Kerbel,et al. Establishing a Link between Oncogenes and Tumor Angiogenesis , 1998, Molecular medicine.
[8] K. Alitalo,et al. Signaling angiogenesis and lymphangiogenesis. , 1998, Current opinion in cell biology.
[9] Harold E. Dvorak,et al. Angiogenesis: a Dynamic Balance of Stimulators and Inhibitors , 1997, Thrombosis and Haemostasis.
[10] B. Teicher,et al. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. , 1992, Cancer research.
[11] E. Keshet,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.
[12] D. Hanahan,et al. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma , 1991, Cell.
[13] I Que,et al. Endostatin inhibits VEGF‐induced endothelial cell migration and tumor growth independently of zinc binding , 1999, The EMBO journal.
[14] B. Zetter,et al. Angiogenesis and tumor metastasis. , 1998, Annual review of medicine.
[15] G. Christofori. The implications of angiogenesis on tumor invasiveness. , 1998, Angiogenesis.
[16] J. Folkman,et al. gro-beta, a -C-X-C- chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice , 1995, The Journal of experimental medicine.
[17] N. Ferrara,et al. OncogenicrasFails to Restore anin VivoTumorigenic Phenotype in Embryonic Stem Cells Lacking Vascular Endothelial Growth Factor (VEGF) , 1999 .
[18] Mark D. Johnson,et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase , 1994, Journal of cellular physiology.
[19] Napoleone Ferrara,et al. Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.
[20] G. Martin,et al. The Role of Basement Membranes in Vascular Development , 1990, Annals of the New York Academy of Sciences.
[21] D. Hanahan,et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[22] Thomas N. Sato,et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.
[23] D. Hanahan,et al. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. , 1999, Cancer research.
[24] E. Borden,et al. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. , 1987, Cancer research.
[25] S. Fox,et al. Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy , 2004, Investigational New Drugs.
[26] Lars Holmgren,et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.
[27] J. Folkman,et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[28] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[29] M. Matsumoto,et al. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[30] A. Logan,et al. Angiogenesis , 1993, The Lancet.
[31] H. Granger,et al. Inhibitory effect of full-length human endostatin on in vitro angiogenesis. , 1999, Biochemical and biophysical research communications.
[32] David W. Dawson,et al. CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells , 1997, The Journal of cell biology.
[33] N. Ferrara,et al. Oncogenic ras fails to restore an in vivo tumorigenic phenotype in embryonic stem cells lacking vascular endothelial growth factor (VEGF). , 1999, Biochemical and biophysical research communications.
[34] Mihaela Skobe,et al. Halting angiogenesis suppresses carcinoma cell invasion , 1997, Nature Medicine.
[35] G. Christofori,et al. Fibroblast Growth Factors in Tumor Progression and Angiogenesis , 1999 .
[36] G. Christofori. The implications of angiogenesison tumor invasiveness , 2004, Angiogenesis.
[37] N. Bouck,et al. Thrombospondin as an Inhibitor of Angiogenesis , 1999 .
[38] R. Xavier,et al. Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.
[39] E. Sage,et al. Angiostatin Diminishes Activation of the Mitogen-Activated Protein Kinases ERK-1 and ERK-2 in Human Dermal Microvascular Endothelial Cells , 1999, Journal of Vascular Research.
[40] P. Campochiaro,et al. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. , 1998, The American journal of pathology.
[41] A. Ullrich,et al. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. , 1993, Cancer research.
[42] J. Folkman,et al. Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.
[43] E. Lander,et al. Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma. , 1995, Cancer research.
[44] N. Ferrara,et al. The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.
[45] T. Danielsen,et al. Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma. , 1998, British Journal of Cancer.
[46] D. Hanahan,et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.
[47] J. Shiloach,et al. Zinc-binding of endostatin is essential for its antiangiogenic activity. , 1998, Biochemical and biophysical research communications.
[48] Thomas N. Sato,et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.
[49] W. Stetler-Stevenson,et al. Tissue inhibitor of metalloproteinases‐2 inhibits bFGF‐induced human microvascular endothelial cell proliferation , 1993, Journal of cellular physiology.
[50] Y. Cao,et al. Endogenous angiogenesis inhibitors: angiostatin, endostatin, and other proteolytic fragments. , 1998, Progress in molecular and subcellular biology.
[51] M. Dewhirst,et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[52] R. Kerbel,et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[53] R. Kerbel. A cancer therapy resistant to resistance , 1997, Nature.
[54] S. Tsang,et al. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[55] S. Mandriota,et al. Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells. , 1998, Experimental cell research.
[56] R. Timpl,et al. Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[57] M. Stack,et al. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. , 1999, The Biochemical journal.
[58] D. Cheresh,et al. Integrins and cancer. , 1996, Current opinion in cell biology.
[59] L. Ellis,et al. Down-regulation of Vascular Endothelial Growth Factor in a Human Colon Carcinoma Cell Line Transfected with an Antisense Expression Vector Specific for c-src * , 1998, The Journal of Biological Chemistry.
[60] K. Dameron,et al. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. , 1994, Cold Spring Harbor symposia on quantitative biology.
[61] Pamela F. Jones,et al. Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.
[62] Thomas Boehm,et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.
[63] A. Aguzzi,et al. Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice. , 1999, The American journal of pathology.
[64] D. Mukhopadhyay,et al. The von Hippel-Lindau Gene Product Inhibits Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Renal Cell Carcinoma by Blocking Protein Kinase C Pathways* , 1997, The Journal of Biological Chemistry.
[65] V. Sukhatme,et al. Endostatin Induces Endothelial Cell Apoptosis* , 1999, The Journal of Biological Chemistry.
[66] W. Risau,et al. Mechanisms of angiogenesis , 1997, Nature.
[67] N. Bouck,et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. , 1998, Blood.
[68] R. Kerbel,et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. , 1995, Cancer research.
[69] D. Cheresh,et al. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. , 1999, The Journal of clinical investigation.
[70] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[71] D. Benezra. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. , 1997, Investigative ophthalmology & visual science.
[72] N. Bouck,et al. How tumors become angiogenic. , 1996, Advances in cancer research.
[73] M. Ittmann,et al. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. , 1999, Human pathology.
[74] A. Friedl,et al. Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding. , 1999, The American journal of pathology.
[75] J. Williams,et al. Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. , 1985, The American journal of pathology.
[76] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[77] Y. Kakeji,et al. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents , 2004, Investigational New Drugs.
[78] Daniel B. Rifkin,et al. Fibroblast Growth Factor-2 (FGF-2) Induces Vascular Endothelial Growth Factor (VEGF) Expression in the Endothelial Cells of Forming Capillaries: An Autocrine Mechanism Contributing to Angiogenesis , 1998, The Journal of cell biology.
[79] D. Hanahan,et al. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. , 1998, The International journal of developmental biology.
[80] D. Taub,et al. Human Interferon-inducible Protein 10 Is a Potent Inhibitor of Angiogenesis in Vivo , 1995 .
[81] R. Timpl,et al. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin , 1999, The EMBO journal.